Nivolumab As Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor

Overview

Journal J Cancer

Specialty Oncology

Date 2017 Mar 7

PMID 28261342

Citations 107

Authors

Liting Guo

Haijun Zhang

Baoan Chen

Affiliations

Soon will be listed here.

Abstract

Targeted immunotherapy has become the most promising approach for tumor patients. Programmed death-1 (PD-1), an inhibitory receptor expressed on activated T cells, can reverse immune suppression and release T cell activation. Nivolumab, a fully human immunoglobulin G4 PD-1 immune checkpoint inhibitor antibody, blocks PD-1 and promotes antitumor immunity, and it is effective for treating non-small-cell lung cancer (NSCLC), melanoma, renal cell carcinoma (RCC) and other cancers. The present review summarizes the efficacy and current status of clinical trials of nivolumab and that enabled nivolumab to be investigated in patients.

Citing Articles

Prognostic Value of Hemoglobin, Albumin, Lymphocyte, Platelet (HALP) Score in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab.

Tomcova Z, Obertova J, Chovanec M, Sycova-Mila Z, Stefanikova K, Slachtova E Biomedicines. 2025; 13(2).

PMID: 40002897 PMC: 11852442. DOI: 10.3390/biomedicines13020484.

Updates in novel immunotherapeutic strategies for relapsed/refractory AML.

Bawek S, Gurusinghe S, Burwinkel M, Przespolewski A Front Oncol. 2024; 14:1374963.

PMID: 39697225 PMC: 11652486. DOI: 10.3389/fonc.2024.1374963.

Current Treatment Methods in Hepatocellular Carcinoma.

Krupa K, Fudalej M, Cencelewicz-Lesikow A, Badowska-Kozakiewicz A, Czerw A, Deptala A Cancers (Basel). 2024; 16(23).

PMID: 39682245 PMC: 11640602. DOI: 10.3390/cancers16234059.

Is nivolumab alone or in combination with ipilimumab more effective for treating lung cancer? a meta-analysis.

Najah Q, Almosilhy N, Ghanm T Eur J Clin Pharmacol. 2024; 81(2):269-278.

PMID: 39680077 DOI: 10.1007/s00228-024-03789-0.

A phase II trial of ipilimumab, nivolumab, or ipilimumab and nivolumab with or without azacitidine in relapsed or refractory myelodysplastic neoplasms.

Bouligny I, Montalban-Bravo G, Sasaki K, Daver N, Jabbour E, Alvarado Y Leukemia. 2024; 39(2):524-528.

PMID: 39551874 DOI: 10.1038/s41375-024-02457-7.

References

Wolchok J, Kluger H, Callahan M, Postow M, Rizvi N, Lesokhin A . Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013; 369(2):122-33. PMC: 5698004. DOI: 10.1056/NEJMoa1302369. View

Gibney G, Kudchadkar R, DeConti R, Thebeau M, Czupryn M, Tetteh L . Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma. Clin Cancer Res. 2014; 21(4):712-20. PMC: 4620684. DOI: 10.1158/1078-0432.CCR-14-2468. View

Asmar R, Yang J, Carvajal R . Clinical utility of nivolumab in the treatment of advanced melanoma. Ther Clin Risk Manag. 2016; 12:313-25. PMC: 4778791. DOI: 10.2147/TCRM.S78039. View

Gettinger S, Horn L, Gandhi L, Spigel D, Antonia S, Rizvi N . Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2015; 33(18):2004-12. PMC: 4672027. DOI: 10.1200/JCO.2014.58.3708. View

Topalian S, Taube J, Anders R, Pardoll D . Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer. 2016; 16(5):275-87. PMC: 5381938. DOI: 10.1038/nrc.2016.36. View

Brahmer J, Drake C, Wollner I, Powderly J, Picus J, Sharfman W . Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010; 28(19):3167-75. PMC: 4834717. DOI: 10.1200/JCO.2009.26.7609. View

Hamanishi J, Mandai M, Ikeda T, Minami M, Kawaguchi A, Murayama T . Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer. J Clin Oncol. 2015; 33(34):4015-22. DOI: 10.1200/JCO.2015.62.3397. View

Nishino M, Sholl L, Hodi F, Hatabu H, Ramaiya N . Anti-PD-1-Related Pneumonitis during Cancer Immunotherapy. N Engl J Med. 2015; 373(3):288-90. PMC: 4539956. DOI: 10.1056/NEJMc1505197. View

Topalian S, Hodi F, Brahmer J, Gettinger S, Smith D, Mcdermott D . Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012; 366(26):2443-54. PMC: 3544539. DOI: 10.1056/NEJMoa1200690. View

10.

Topalian S, Weiner G, Pardoll D . Cancer immunotherapy comes of age. J Clin Oncol. 2011; 29(36):4828-36. PMC: 3255990. DOI: 10.1200/JCO.2011.38.0899. View

11.

Mashima E, Inoue A, Sakuragi Y, Yamaguchi T, Sasaki N, Hara Y . Nivolumab in the treatment of malignant melanoma: review of the literature. Onco Targets Ther. 2015; 8:2045-51. PMC: 4532168. DOI: 10.2147/OTT.S62102. View

12.

Worley L . Cabozantinib and nivolumab for renal cell carcinoma. Lancet Oncol. 2015; 16(15):e531. DOI: 10.1016/S1470-2045(15)00377-0. View

13.

Postow M, Chesney J, Pavlick A, Robert C, Grossmann K, McDermott D . Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015; 372(21):2006-17. PMC: 5744258. DOI: 10.1056/NEJMoa1414428. View

14.

Hawkes E, Grigg A, Chong G . Programmed cell death-1 inhibition in lymphoma. Lancet Oncol. 2015; 16(5):e234-45. DOI: 10.1016/S1470-2045(15)70103-8. View

15.

. Dramatic Survival Benefit with Nivolumab in Melanoma. Cancer Discov. 2016; 6(6):OF7. DOI: 10.1158/2159-8290.CD-NB2016-044. View

16.

Yaqub F . Nivolumab for squamous-cell non-small-cell lung cancer. Lancet Oncol. 2015; 16(7):e319. DOI: 10.1016/S1470-2045(15)00033-9. View

17.

Carlo-Stella C, Santoro A . Microenvironment-related biomarkers and novel targets in classical Hodgkin's lymphoma. Biomark Med. 2015; 9(8):807-17. DOI: 10.2217/BMM.15.30. View

18.

Sundar R, Cho B, Brahmer J, Soo R . Nivolumab in NSCLC: latest evidence and clinical potential. Ther Adv Med Oncol. 2015; 7(2):85-96. PMC: 4346216. DOI: 10.1177/1758834014567470. View

19.

Ansell S, Lesokhin A, Borrello I, Halwani A, Scott E, Gutierrez M . PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med. 2014; 372(4):311-9. PMC: 4348009. DOI: 10.1056/NEJMoa1411087. View

20.

Motzer R, Rini B, Mcdermott D, Redman B, Kuzel T, Harrison M . Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. J Clin Oncol. 2014; 33(13):1430-7. PMC: 4806782. DOI: 10.1200/JCO.2014.59.0703. View